AstraZeneca's gene-silencing drug trial disappoints; co-treatment may explain setback

A high-profile study of AstraZeneca and Ionis Pharmaceuticals' Wainua for heart disease failed unexpectedly, according to the trial's lead investigator. The failure may be linked to patients concurrently taking a Pfizer medication for the same condition, which could have confounded results. The outcome raises questions about the drug's future development path.